Compare Amphastar Pharmaceuticals Inc (AMPH) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Annaly Capital Management, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Annaly Capital Management, Inc. trades at $23.21 (market cap $17.27B). The key difference: Annaly Capital Management, Inc. is far larger — about 20× Amphastar Pharmaceuticals Inc's market cap, and Annaly Capital Management, Inc. pays a 13.09% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | NLY | |
|---|---|---|
Market Cap | $863.95M | $17.27B |
Sector | Health | Financials |
52-Week High | $30.81 | $24.40 |
52-Week Low | $16.87 | $20.21 |
Enterprise Value | $1.26B | — |
Dividend Yield | — | 13.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Annaly Capital Management (NLY) trades at $23.04, up 1.68% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows robust fundamentals with a P/E of 5.57, ROE of 20.66%, and a net income margin of 92.77%. Recent news highlights inclusion in Zacks' Strong Buy lists and a focus on high-yield income, supported by a $0.75 dividend payment scheduled for July 2026.
Outlook is positive with analyst consensus favoring Buy ratings (57.15%) and a $24.50 price target, implying ~6% upside. Key risks include interest rate sensitivity and mortgage market volatility, but diversified housing finance strategies and consistent dividend coverage provide stability. Investment appeal centers on value valuation and income generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
